Skip to content

MAZE MAZE Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.26B+31.9%
Septerna, Inc. logo
Septerna, Inc.SEPN
$100K+270%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$991K-47.1%
Zymeworks logo
ZymeworksZYME
$278K-67.5%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$20K0.0%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$62K+1,140%

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.48B
Enterprise value$1.34B
P/S7.9×

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Reported directly by MAZE in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's other non-current liabilities?
MAZE (MAZE) reported other non-current liabilities of $388K in Q1 2026.
How has MAZE's other non-current liabilities changed year-over-year?
MAZE's other non-current liabilities decreased by 61.4% year-over-year, from $1.01M to $388K.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.